Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways

INTRODUCTION: Osteoporosis is an osteolytic bone condition characterized by decreased bone strength and increased bone fragility. It is the result of elevated formation or activity of bone-resorbing osteoclasts. Although current therapeutic agents are efficacious against osteoclast-mediated bone los...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Drug Des Devel Ther
Egile Nagusiak: Li, Xuedong, Lin, Xixi, Wu, Zuoxing, Su, Yuangang, Liang, Jiamin, Chen, Runfeng, Yang, Xue, Hou, Lei, Zhao, Jinmin, Liu, Qian, Xu, Feng
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove 2021
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7800467/
https://ncbi.nlm.nih.gov/pubmed/33442237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S283694
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak